eribulin vs capecitabine | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | 0.88 [0.77 1.00] | p=1.00 | 0 | 1102 | 1 | Trial 301 (Kaufman), | progression or death (progression free survival PFS) | 1.08 [0.93 1.25] | p=1.00 | 0 | 1102 | 1 | Trial 301 (Kaufman), | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin vs ixabepilone | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin vs paclitaxel | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin vs treatment of physician | death (overall survival) by 19% (fully demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | 0.81 [0.66 0.99] | p=0.04 | 0 | 762 | 1 | EMBRACE (Cortes), | progression or death (progression free survival PFS) | 0.87 [0.72 1.06] | p=1.00 | 0 | 762 | 1 | EMBRACE (Cortes), | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin vs vinorelbine | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin+cyclophosphamide vs docetaxel+cyclophosphamide | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
eribulin+gemcitabine vs paclitaxel+gemcitabine | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |